Category: Press Releases

FOR IMMEDIATE RELEASE LEADING EXPERTS PUBLISH A ROADMAP FOR CRITICAL AREAS OF RESEARCH IN AMYLOIDOSIS (more…)

Earlier this month, Pfizer announced that it has made two separate FDA submissions for their drug tafamidis, based on evidence generated from the Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) clinical trial, (more…)

The UK’s National Institute for Health and Care Excellence (NICE) has published Evaluation Consultation Documents on its assessments of inotersen and patisiran. (more…)

Amyloidosis Research Consortium Announces Publication of Seminal Manuscript in Peer-Reviewed Journal Leukemia Encouraging Use of NT-proBNP as Endpoint in Clinical Trials. International AL amyloidosis expert community agrees N-terminal pro-brain natriuretic peptide (NT-proBNP) is analytically validated and clinically qualified to be...

Amyloidosis Research Consortium Calls For Regulators To Adopt New Surrogate End Point For Pivotal Clinical Trials In Patients with AL Amyloidosis Cardiac functional biomarker is a validated end point used universally by amyloidosis specialists to determine treatment outcomes and to...